SEC filing · 8-K

Zymeworks Inc.: Acquisition or sale completed

Zymeworks completed its acquisition of Theravance Biopharma for $17.00 per share in cash plus contingent value rights.

Filed September 23, 2026

Positive for the company

What happened

On September 23, 2026, Zymeworks completed the merger with Theravance Biopharma, making Theravance a wholly owned subsidiary.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Zymeworks Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.